Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q3 2018 (← Previous) (Next →)

Filing Date: Nov 14, 2018

Total Value ($000): $453,306 (100.0% shares, 0.0% debt)

Holdings (9)

BIIB BIOGEN INC. 36.0%

Value ($000) $163,179 Shares 461,858 Est. Cost $285.21 Unrealized +20.7%

INVA INNOVIVA INC. 15.2%

Value ($000) $69,113 Shares 4,535,000 Est. Cost $11.88 Unrealized +21.2%

— ALLERGAN PLC 14.5%

Value ($000) $65,525 Shares 344,000 Est. Cost $164.77 Unrealized —

IRWD IRONWOOD PHARMACEUTICALS INC. 13.7%

Value ($000) $62,156 Shares 3,367,100 Est. Cost $12.76 Unrealized +23.9%

— MEDICINES CO. 12.7%

Value ($000) $57,487 Shares 1,922,000 Est. Cost $29.43 Unrealized —

— INTERCEPT PHARMACEUTICALS INC. 7.2%

Value ($000) $32,537 Shares 257,500 Est. Cost $60.63 Unrealized —

— NOVELION THERAPEUTICS INC. 0.7%

Value ($000) $3,034 Shares 1,025,000 Est. Cost $8.42 Unrealized —

— SHIRE PLC 0.0%

Value ($000) $181 Shares 1,000 Est. Cost $152.21 Unrealized —

ABBV ABBVIE INC. 0.0%

Value ($000) $94 Shares 1,000 Est. Cost $38.85 Unrealized +78.1%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
BIIB	BIOGEN INC.	461,858	$163,179	36.0%	$285.21	+20.7%	COM	09062X103
INVA	INNOVIVA INC.	4,535,000	$69,113	15.2%	$11.88	+21.2%	COM	45781M101
—	ALLERGAN PLC	344,000	$65,525	14.5%	$164.77	—	SHS	G0177J108
IRWD	IRONWOOD PHARMACEUTICALS INC.	3,367,100	$62,156	13.7%	$12.76	+23.9%	COM CL A	46333X108
—	MEDICINES CO.	1,922,000	$57,487	12.7%	$29.43	—	COM	584688105
—	INTERCEPT PHARMACEUTICALS INC.	257,500	$32,537	7.2%	$60.63	—	COM	45845P108
—	NOVELION THERAPEUTICS INC.	1,025,000	$3,034	0.7%	$8.42	—	COM NEW	67001K202
—	SHIRE PLC	1,000	$181	0.0%	$152.21	—	SPONSORED ADR	82481R106
ABBV	ABBVIE INC.	1,000	$94	0.0%	$38.85	+78.1%	COM	00287Y109